Breathe Well Live Well
Condition: Asthma
Intervention: Drug: Busonid (budesonide 200mcg and 400mcg)
Sponsor: Ache Laboratorios Farmaceuticos S.A.
Not yet recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
| Related Articles |
Caregiver treatment satisfaction is improved together with children’s asthma control: Prospective study for budesonide monotherapy in school-aged children with uncontrolled asthma symptoms.
Allergol Int. 2015 Oct;64(4):371-6
Authors: Yoshihara S, Kanno N, Fukuda H, Arisaka O, Arita M, Sekine K, Yamaguchi K, Tsuchida A, Yamada Y, Watanabe T, Shimizu T, Nishikawa K, Nishimuta T
Abstract
BACKGROUND: If asthmatic children cannot obtain sufficient control of their disease, not only do they suffer from asthma symptoms, but the daily life activities of their caregivers are also disrupted. We investigated the effectiveness of an inhaled corticosteroid (ICS) for symptom control in previously ICS-untreated school-aged asthmatic children as well as caregiver treatment satisfaction (CTS).
METHODS: A multicenter, open-label, single-arm study on 12-week ICS (budesonide Turbuhaler(®)) monotherapy was undertaken in subjects aged 5-15 years with bronchial asthma not treated with ICS during the previous 3 months. At 0, 4, 8, and 12 weeks after start of ICS administration, Japanese Pediatric Asthma Control Program (JPAC) scores, and CTS scores were summated and lung function measured. At weeks 0 and 12, questionnaires on caregiver anxiety were also assessed.
RESULTS: Seventy-five patients were enrolled, and 69 assessed. Ninety percent of subjects had been treated with asthma controller medication except ICS before study enrollment. JPAC score and CTS score were improved significantly at weeks 4, 8, and 12 (p < 0.001). With regard to CTS, more than half of caregivers showed a perfect score at weeks 8 and 12. There was a significant correlation between JPAC score and CTS score. Lung function and caregiver anxiety were also improved, and good compliance with treatment was observed during the intervention.
CONCLUSIONS: If treating ICS-untreated school-aged asthmatic children with uncontrolled symptoms, ICS monotherapy can improve CTS along with improving asthma control.
PMID: 26433534 [PubMed – in process]
View full post on pubmed: asthma
Condition: Eosinophilic Esophagitis
Interventions: Drug: Budesonide effervescent 0.5mg tablet twice daily; Drug: Budesonide effervescent 1mg tablet twice daily; Drug: Placebo effervescent tablet twice daily
Sponsor: Dr. Falk Pharma GmbH
Not yet recruiting – verified July 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Bronchial Asthma
Interventions: Drug: Intravenous magnesium sulfate; Drug: Inhaled budesonide; Drug: normal saline
Sponsor: Hamad Medical Corporation
Recruiting – verified May 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Budesonide comparable to methylprednisolone for pediatric bronchial asthma …
Healio Methylprednisolone and budesonide inhalation suspension showed limited differences regarding the severity of attacks, duration of management, duration of wheezing and hospitalization in patients with moderate bronchial asthma attacks, according to … |
View full post on asthma – Google News
|
Budesonide, formoterol regular therapy better for moderate asthma
Healio “Our results show that as-needed budesonide and formoterol is inferior to regular budesonide and formoterol plus as-needed terbutaline in preventing treatment failure and in maintaining asthma control,” Alberto Papi, MD, of the department of … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Respimat® Budesonide low dose; Drug: Respimat® Budesonide high dose; Drug: Turbohaler® Budesonide; Drug: Placebo
Sponsor: Boehringer Ingelheim
Completed – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Budesonide Inhalation Aerosol (PT008) Dose 1; Drug: Budesonide Inhalation Aerosol (PT008) Dose 2; Drug: Budesonide Inhalation Aerosol (PT008) Dose 3; Drug: Budesonide Inhalation Aerosol (PT008) Dose 4; Drug: Placebo
Sponsor: Pearl Therapeutics, Inc.
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX; Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarate
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified February 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 |
Multiple In Vitro and In Vivo Regulatory Effects of Budesonide in CD4+ T Lymphocyte Subpopulations of Allergic Asthmatics.
PLoS One. 2012;7(12):e48816
Authors: Pace E, Di Sano C, La Grutta S, Ferraro M, Albeggiani G, Liotta G, Di Vincenzo S, Uasuf CG, Bousquet J, Gjomarkaj M
Abstract
BACKGROUND: Increased activation and increased survival of T lymphocytes characterise bronchial asthma.
OBJECTIVES: In this study the effect of budesonide on T cell survival, on inducible co-stimulator T cells (ICOS), on Foxp3 and on IL-10 molecules in T lymphocyte sub-populations was assessed.
METHODS: Cell survival (by annexin V binding) and ICOS in total lymphocytes, in CD4+/CD25+ and in CD4+/CD25- and Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25-cells was evaluated, by cytofluorimetric analysis, in mild intermittent asthmatics (n?=?19) and in controls (n?=?15). Allergen induced T lymphocyte proliferation and the in vivo effects of budesonide in mild persistent asthmatics (n?=?6) were also explored.
RESULTS: Foxp3 was reduced in CD4+/CD25- and in CD4+/CD25+ cells and ICOS was reduced in CD4+/CD25+ cells but it was increased in CD4+CD25-in asthmatics when compared to controls. In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation. In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.
CONCLUSIONS: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-populations. The findings provided shed light on new mechanisms by which corticosteroids, drugs widely used for the clinical management of bronchial asthma, control T lymphocyte activation.
PMID: 23251336 [PubMed – in process]
View full post on pubmed: asthma